BMS-650032
Sponsors
Bristol-Myers Squibb
Conditions
Chronic Hepatitis CHepatic InsufficiencyHepatitis CHepatitis C InfectionHepatitis C Virus
Phase 1
Drug-Drug Interaction Study in Healthy Subjects
CompletedNCT00904059
Start: 2009-05-31End: 2009-07-31Updated: 2011-01-07
Hepatic Impaired Subjects Compared to Healthy Subjects Receiving Multi-dose BMS-650032
CompletedNCT01019070
Start: 2009-12-31End: 2011-08-31Updated: 2011-10-26
Drug Interaction Oral Contraceptive Pill (OCP)
CompletedNCT01063023
Start: 2010-01-31End: 2010-06-30Updated: 2011-01-25
Phase 2
A Multiple Ascending Dose Study of BMS-650032 in HCV Infected Subjects
CompletedNCT00722358
Start: 2008-12-31End: 2009-12-31Updated: 2011-06-27
Study to Determine the Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Failed Standard of Care
CompletedNCT01012895
Start: 2009-12-31End: 2014-02-28Updated: 2015-10-09
Study of BMS-650032 With Peginterferon Alfa-2a Plus Ribavirin
CompletedNCT01030432
Start: 2010-02-28End: 2012-10-31Updated: 2015-10-09
An Anti-viral Combination Study With Japanese Hepatitis C Infection (HCV) Subject
CompletedNCT01051414
Start: 2010-04-30End: 2012-05-31Updated: 2015-10-09
Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available Medications
CompletedNCT01455090
Start: 2011-11-30End: 2015-07-31Updated: 2017-04-27